On April 17th 2026, VectorB2B brings together strategic and operational stakeholders involved in clinical research to foster collaboration, identify opportunities for innovation and strengthen the quality and impact of clinical research in Portugal.
We are part of the EIC Service Catalogue, supporting beneficiaries in both preclinical and clinical development
We are pleased to share our participation in the June/July edition of Business Portugal magazine, where our Co-CEOs, Ana Custódio and Francisco Castro, highlight the journey of VectorB2B as a center of innovation in health.
VectorB2B design and execute your preclinical GLP/ non-GLP toxicology studies, ensuring the success of your drug/health product development program while meeting global standards and specifications for quality and compliance